MAPT and Alzheimer disease: The co-treatment significantly enhanced spatial learning and memory, attenuated neuroinflammatory cytokines (IL-6 and TNF-α), downregulated AD-associated proteins (APP and MAPT), and restored antioxidant capacity by increasing SOD activity and decreasing MDA levels.